DNLI - Denali Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.549B

Cash

936.9M

Avg Qtr Burn

-103.2M

Short % of Float

5.75%

Insider Ownership

13.72%

Institutional Own.

84.60%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DNL310 (ETV:IDS) Details Hunter syndrome MPS II	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DNL343 (eIF2B Activator) Details Amyotrophic lateral sclerosis	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BIIB122/DNL151 (LRRK2 Inhibitor) Details Parkinson's disease	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DNL758 (CNS-penetrant RIPK1 inhibitor) Details Lupus nephritis, Cutaneous lupus erythematosus, Ulcerative colitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SAR443820/DNL788 (CNS-Penetrant RIPK1 Inhibitor) Details Multiple sclerosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TAK-594/DNL593 (PTV:PGRN) Details Frontotemporal dementia with GRN mutations	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DNL126 (ETV:SGSH) Details Sanfilippo Syndrome	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SAR443820/DNL788 (CNS-Penetrant RIPK1 Inhibitor) Details Amyotrophic lateral sclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.